Development of peptides as potential drugs for cancer therapy

Current Pharmaceutical Design

Volumn 16, Issue 10, 2010, Pages 1180-1189

  Li, Zhi Jie ^a   Cho, Chi Hin ^a  

^a Chinese University of Hong Kong   (Hong Kong)

Author keywords

Cancer therapy; Inhibitor; Peptide; Peptide library; Phage display; Targeting peptide

Indexed keywords

AH 111585; ANTIBODY; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CYCLIN DEPENDENT KINASE 2; DEXTRO AMINO ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 6 RECEPTOR; MATRIX METALLOPROTEINASE 14; PEPTIDE DERIVATIVE; PROTEIN P53; RAS PROTEIN; SCAFFOLD PROTEIN; SCATTER FACTOR; STAT3 PROTEIN; THROMBOPOIETIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; DRUG CONJUGATION; DRUG DESIGN; DRUG HALF LIFE; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; PEPTIDES; SIGNAL TRANSDUCTION;

EID: 77950914950     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790945913     Document Type: Review

References (139)

1. Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat 2009; 12: 65-73.
2. Borghouts C, Kunz C, Groner B. Peptide aptamers: recent developments for cancer therapy. Expert Opin Biol Ther 2005; 5:783-797 (Pubitemid 40873887)
3. Kim JW, Wang XW. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 2003; 24: 363-369
4. Loud JT, Peters JA, Fraser M, Jenkins J. Applications of advances in molecular biology and genomics to clinical cancer care. Cancer Nurs 2002; 25: 110-22; quiz 23-24 (Pubitemid 34263935)
5. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002; 57:749-763 (Pubitemid 35279166)
6. Mendoza FJ, Espino PS, Cann KL, Bristow N, McCrea K, Los M. Anti-tumor chemotherapy utilizing peptide-based approaches - apoptotic pathways, kinases, and proteasome as targets. Arch Immunol Ther Exp (Warsz) 2005; 53: 47-60. (Pubitemid 40364725)
7. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004; 2: 170-182 (Pubitemid 39030307)
8. Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci 2005; 11:713-726 (Pubitemid 41684258)
9. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004; 3: 349-380
10. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9: 1566-1572 (Pubitemid 36418415)
11. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317
12. Sidhu SS. Engineering M13 for phage display. Biomol Eng 2001; 18: 57-63.
13. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev 2005; 105: 4056-4072
14. Hartley O. The use of phage display in the study of receptors and their ligands. J Recept Signal Transduct Res 2002; 22: 373-392 (Pubitemid 36169159)
15. Mersich C, Jungbauer A. Generation of bioactive peptides by biological libraries. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 861: 160-170
16. Manoutcharian K, Gevorkian G, Cano A, Almagro JC. Phage displayed biomolecules as preventive and therapeutic agents. Curr Pharm Biotechnol 2001; 2: 217-223 (Pubitemid 32798797)
17. Rodi DJ, Makowski L. Phage-display technology--finding a needle in a vast molecular haystack. Curr Opin Biotechnol 1999; 10: 87-93. (Pubitemid 29054632)
18. Nilsson F, Tarli L, Viti F, Neri D. The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 2000; 43: 165-196
19. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000; 11: 610-616
20. Willats WG. Phage display: practicalities and prospects. Plant Mol Biol 2002; 50: 837-854
21. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 2004; 10: 2335-2343 (Pubitemid 38855040)
22. Schaedel O, Reiter Y. Antibodies and their fragments as anticancer agents. Curr Pharm Des 2006; 12: 363-378
23. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004; 9: 525-529 (Pubitemid 38739333)
24. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-554 (Pubitemid 120015109)
25. Buckler DR, Park A, Viswanathan M, Hoet RM, Ladner RC. Screening isolates from antibody phage-display libraries. Drug Discov Today 2008; 13: 318-324 (Pubitemid 351474596)
26. George AJ, Lee L, Pitzalis C. Isolating ligands specific for human vasculature using in vivo phage selection. Trends Biotechnol 2003; 21: 199-203.
27. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007; 4: 631-651
28. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immuno - conjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52: 328-337 (Pubitemid 36578026)
29. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995; 28: 126-142
30. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52: 281-296 (Pubitemid 36578023)
31. Ringe D. What makes a binding site a binding site? Curr Opin Struct Biol 1995; 5: 825-829
32. Mattos C, Ringe D. Locating and characterizing binding sites on proteins. Nat Biotechnol 1996; 14: 595-599 (Pubitemid 26135122)
33. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003; 63: 1288-1296
34. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-994
35. Pugliese A. Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword. J Clin Invest 2003; 111: 1280-1282 (Pubitemid 36554697)
36. Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. Oncologist 2003; 8 Suppl 3: 5-17. (Pubitemid 37523378)
37. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006; 42: 290-294 (Pubitemid 43132883)
38. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393: 83-85 (Pubitemid 28240259)
39. Prenzel N, Zwick E, Leserer M, Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2000; 2: 184-190
40. Houimel M, Schneider P, Terskikh A, Mach JP. Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer 2001; 92: 748-755 (Pubitemid 32385720)
41. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 2002; 21: 287-296
42. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer 2004; 111: 951-960
43. Urbanelli L, Ronchini C, Fontana L, Menard S, Orlandi R, Monaci P. Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. J Mol Biol 2001; 313:965-976
44. Kunz C, Borghouts C, Buerger C, Groner B. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Mol Cancer Res 2006; 4: 983-998
45. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 2002; 277: 43137-43142
46. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000; 20: 214-232
47. Serrati S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, Dotor J, et al. TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. Biochem Pharmacol 2009; 77: 813-825
48. Cardo-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, et al. A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One 2008; 3: e3452.
49. Dotor J, Lopez-Vazquez AB, Lasarte JJ, Sarobe P, Garcia-Granero M, Riezu- Boj JI, et al. Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine 2007; 39: 106-115
50. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 2005; 65:4827-4835
51. Zozulya S, Lioubin M, Hill RJ, Abram C, Gishizky ML. Mapping signal transduction pathways by phage display. Nat Biotechnol 1999; 17: 1193-1198
52. Sparks AB, Rider JE, Hoffman NG, Fowlkes DM, Quillam LA, Kay BK. Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2. Proc Natl Acad Sci USA 1996; 93: 1540-1544
53. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol 2004; 1: 113-132
54. Wu L, Johnson M, Sato M. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med 2003; 9: 421-429
55. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev 2009; 61: 572-588
56. Vousden KH, Farrell PJ. Viruses and human cancer. Br Med Bull 1994; 50: 560-581
57. Zhou PK, Sun Y, An J. Interaction between viral proteins and hosts and its disturbance in the cellular responses to ionising radiation. Int J Radiat Biol 2009; 85: 587-597
58. Fujii T, Austin D, Guo D, Srimatkandada S, Wang T, Kubushiro K, et al. Peptides inhibitory for the transcriptional regulatory function of human papillomavirus E2. Clin Cancer Res 2003; 9: 5423-5428
59. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003; 1: 1001-1008
60. Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98: 12438-12443
61. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13: 2141-2147 (Pubitemid 26411564)
62. Burch L, Shimizu H, Smith A, Patterson C, Hupp TR. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol 2004; 337: 129-145 (Pubitemid 38270252)
63. Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R, et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 1999; 18: 4357-4363 (Pubitemid 29392376)
64. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996; 380: 548-550 (Pubitemid 26110646)
65. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 2001; 98: 1773-1781
66. Xu CW, Luo Z. Inactivation of Ras function by allele-specific peptide aptamers. Oncogene 2002; 21: 5753-5757 (Pubitemid 35333008)
67. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007; 13: 535-541 (Pubitemid 350123764)
68. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 337-376 (Pubitemid 36382891)
69. Wittekind C, Neid M. Cancer invasion and metastasis. Oncology 2005; 69 Suppl 1: 14-16
70. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009; 34: 881-895
71. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55-63.
72. Kridel SJ, Sawai H, Ratnikov BI, Chen EI, Li W, Godzik A, et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002; 277: 23788-23793 (Pubitemid 34952221)
73. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003; 100: 5778-5782 (Pubitemid 36576884)
74. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009; 69: 1517-1526
75. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 768-774 (Pubitemid 29365104)
76. Mueller J, Gaertner FC, Blechert B, Janssen KP, Essler M. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol Cancer Res 2009; 7: 1078-1085
77. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26. (Pubitemid 40732764)
78. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-2214
79. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300. (Pubitemid 37328782)
80. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-361 (Pubitemid 38340304)
81. Tam EM, Runyon ST, Santell L, Quan C, Yao X, Kirchhofer D, et al. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide. J Mol Biol 2009; 385: 79-90.
82. Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, et al. Identification of a met-binding peptide from a phage display library. Clin Cancer Res 2007; 13: 6049-6055 (Pubitemid 350075061)
83. Yang W, Luo D, Wang S, Wang R, Chen R, Liu Y, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 2008; 14: 5494-5502
84. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
85. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001; 5: 308-313 (Pubitemid 32718528)
86. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002; 6: 399-404.
87. Laakkonen P, Zhang L, Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann NY Acad Sci 2008; 1131: 37-43. (Pubitemid 351758501)
88. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90.
89. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-366
90. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380 (Pubitemid 28063372)
91. Trepel M, Pasqualini R, Arap W. Chapter 4. Screening phage-display Peptide libraries for vascular targeted peptides. Methods Enzymol 2008; 445: 83-106.
92. Christianson DR, Ozawa MG, Pasqualini R, Arap W. Techniques to decipher molecular diversity by phage display. Methods Mol Biol 2007; 357: 385-406. (Pubitemid 350183263)
93. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006; 16: 80-88
94. Newton JR, Deutscher SL. In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods Mol Biol 2009; 504: 275-290
95. Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 2007; 35:780-783 (Pubitemid 47310367)
96. Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J Control Release 2003; 91:183-186 (Pubitemid 37288889)
97. Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, Wang YP, et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 2009; 284: 12905-12916
98. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-α with αV integrin ligands improves its antineoplastic activity. Cancer Res 2004; 64: 565-571
99. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10:625-632 (Pubitemid 38796854)
100. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-1175
101. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY) 1995; 13: 265-270
102. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-727 (Pubitemid 30094573)
103. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-1038 (Pubitemid 29439574)
104. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99: 1527-1531 (Pubitemid 34136526)
105. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003; 4: 393-403. (Pubitemid 37491100)
106. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003; 4: 383-391
107. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007; 67: 10958-10965
108. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006; 30: 351-367
109. Funke SA, Willbold D. Mirror image phage display - a method to generate D-peptide ligands for use in diagnostic or therapeutical applications. Mol Biosyst 2009; 5: 783-786
110. Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006; 17: 638-642
111. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer 1999; 83: 326-334
112. Klevenz B, Butz K, Hoppe-Seyler F. Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding. Cell Mol Life Sci 2002; 59:1993-1998
113. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, et al. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 2006; 1758: 384-393
114. Tilstra J, Rehman KK, Hennon T, Plevy SE, Clemens P, Robbins PD. Protein transduction: identification, characterization and optimization. Biochem Soc Trans 2007; 35: 811-815
115. Beerens AM, Al Hadithy AF, Rots MG, Haisma HJ. Protein transduction domains and their utility in gene therapy. Curr Gene Ther 2003; 3: 486-494
116. Bernkop-Schnurch A, Schmitz T. Presystemic metabolism of orally administered peptide drugs and strategies to overcome it. Curr Drug Metab 2007; 8: 509-517
117. Snyder EL, Meade BR, Dowdy SF. Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. J Control Release 2003; 91: 45-51.
118. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 2004; 101: 9381-9386
119. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002; 8: 751-755
120. Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001; 61: 2434-2438
121. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-1822 (Pubitemid 38374867)
122. Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007; 96: 2547-2565 (Pubitemid 47603100)
123. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008; 105: 9343-9348
124. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 2009; 4: e4171.
125. Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 2008; 7:579-589 (Pubitemid 351482141)
126. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci 2009; 14: 887-899
127. Liu Z, Niu G, Shi J, Liu S, Wang F, Liu S, et al. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009; 36: 947-957
128. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging 2009; 36:1296-1307
129. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42: 326-336 (Pubitemid 32150525)
130. Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008; 14:454-458
131. Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 2008; 5: e85. (Pubitemid 351649264)
132. Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res 2008; 68: 2286-2291 (Pubitemid 351521802)
133. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, libraryderived fluorescent peptide. Cancer Res 2004; 64: 6247-6251 (Pubitemid 39129427)
134. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407 (Pubitemid 34734217)
135. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC, 3rd, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125: 385-398
136. Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009; 115: 128-139
137. Han TS, Teichert RW, Olivera BM, Bulaj G. Conus venoms - a rich source of peptide-based therapeutics. Curr Pharm Des 2008; 14(24): 2462-2479
138. Marchioni F, Zheng Y. Targeting rho GTPases by peptidic structures. Curr Pharm Des 2009; 15(21): 2481-2487
139. Vazquez E, Ferrer-Miralles N, Mangues R, Corchero JL, Schwartz S. Jr, Villaverde A. Modular protein engineering in emerging cancer therapies. Curr Pharm Des 2009; 15(8): 893-916.